The Food and Drug Administration has approved a Medtronic device to lower blood pressure, the company announced Friday evening. The decision comes after an advisory panel narrowly voted against the device in August.
The FDA approved a similar product, part of a device class called renal denervation, from startup Recor Medical earlier this month.
“Medtronic has always believed in the potential of this therapy,” Jason Weidman, renal denervation head at Medtronic, said in a statement. “We partnered closely with leading experts in our clinical community who could help us in our journey to get this technology to the people who need it most.”
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect